NRG Oncology RTOG 1016: radiotherapy plus cetuximab versus cisplatin in HPV-positive oropharyngeal cancer
Trying to reduce toxicity by swapping cisplatin for cetuximab during radiotherapy in HPV-positive oropharyngeal cancer backfired: cetuximab gave worse survival and more recurrences with no reduction in toxicity, so cisplatin remains standard.
Overview
Phase 3 non-inferiority trial of 849 patients with HPV-positive (p16-positive) oropharyngeal cancer randomised to accelerated intensity-modulated radiotherapy with cisplatin or with cetuximab.
Five-year overall survival was 77.9 percent with cetuximab against 84.6 percent with cisplatin (hazard ratio 1.45, non-inferiority not met) and five-year locoregional failure 17.3 versus 9.9 percent; acute and late toxicity rates were similar.
- Five-year overall survival 77.9 percent (cetuximab) vs 84.6 percent (cisplatin); hazard ratio 1.45.
- Five-year locoregional failure 17.3 percent vs 9.9 percent.
Cisplatin chemoradiation is the standard for HPV-positive oropharyngeal cancer; cetuximab is reserved for patients who cannot receive cisplatin.
- Accelerated radiotherapy fractionation differs from standard practice in some countries.
Similar pages
not linked directly; found by shared links- Key paperDe-ESCALaTE HPV: radiotherapy plus cisplatin or cetuximab in low-risk HPV-positive oropharyngeal cancer
Shares Oropharyngeal cancer (tonsil and base of tongue), HPV-positive oropharyngeal cancer, The Lancet, Cetuximab.
- TrialORATOR
Shares Oropharyngeal cancer (tonsil and base of tongue), HPV-positive oropharyngeal cancer, Cisplatin.
- TrialDe-ESCALaTE HPV
Shares Oropharyngeal cancer (tonsil and base of tongue), HPV-positive oropharyngeal cancer, Cetuximab, Cisplatin.
- TrialA Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Shares Oropharyngeal cancer (tonsil and base of tongue), HPV-positive oropharyngeal cancer.
- Key paperHuman papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)
Shares Oropharyngeal cancer (tonsil and base of tongue), HPV-positive oropharyngeal cancer.
- TrialPATHOS
Shares Oropharyngeal cancer (tonsil and base of tongue), HPV-positive oropharyngeal cancer, Cisplatin.
- TrialECOG-ACRIN E3311
Shares Oropharyngeal cancer (tonsil and base of tongue), HPV-positive oropharyngeal cancer, Cisplatin.
- TrialRRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Shares Oropharyngeal cancer (tonsil and base of tongue), Cisplatin.